Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit
Yıl: 2023 Cilt: 63 Sayı: 1 Sayfa Aralığı: 40 - 45 Metin Dili: İngilizce DOI: 10.14744/hnhj.2021.60024 İndeks Tarihi: 28-05-2023
Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit
Öz: Introduction: The risk of thromboembolism increases due to tendency to coagulopathy, excessive inflammation, hypoxia, and immobility in patients who are treated of COVID-19 in Intensive Care Units (ICU). Therefore, thromboembolism pro- phylaxis (anticoagulant therapy) is recommended. There is no clear recommendation in the literature regarding the dose and duration of anticoagulant therapy. In this study, we evaluate of two different anticoagulant administrations in terms of prognosis and mortality in COVID-19 patients who were followed up and treated in the ICU. Methods: After the approval of the Ethics Committee, the study was carried out by retrospectively in ICU affiliated to three different centers. The patients were divided into two groups as those using anticoagulant at a prophylactic dose (Group 1) and treatment dose (Group 2). Various parameters of the patients were evaluated. Results: Of the 91 patients included in the study, 61.5% received prophylactic and 38.5% therapeutic anticoagulants. The rate of male patients 73.9% was found to be significantly higher in the mortal group (p=0.014). About 75.9% of the patients who received mechanical ventilation treatment and 13.59% of the patients who were not applied died (p<0.001). Mortality was higher in the group using prophylactic anticoagulants (58.39% vs. 37.1% p;0.043). Patients using prophylactic doses of anticoagulants had 2.42 times more mortality (Odds Ratio=2.42). Hb levels were found to be lower (p=0.017) and pro- thrombin time and partial prothrombine time values were long (p=0.048 and 0.038, respectively) in patients who received anticoagulants at the treatment dose. Discussion and Conclusion: Despite the increased tendency for thrombosis in COVID-19, there is no clear preventive or protective treatment. Hence, if there is no contraindicated situation, we believe that anticoagulants can be used safely at the treatment dose to avoid possible thromboembolic complications and reduce the risk of mortality. There is a need for large- scale studies on dose selection in terms of prophylaxis.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parame- ters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7.
- 2. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 2020;382:872–4.
- 3. Léonard-Lorant I, Delabranche X, Séverac F, Helms J, Pauzet C, Collange O, et al. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to d-dimer levels. Radiology 2020;296:E189–91.
- 4. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gom- mers DAMPJ, Kant KM, et al. Incidence of thrombotic compli- cations in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.
- 5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, China Medical Treat- ment Expert Group for Covid-19, et al. Clinical character- istics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.
- 6. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Drig- gin E, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:2950–73.
- 7. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treat- ment is associated with decreased mortality in severe coro- navirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094–9.
- 8. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res 2017;149:38–44.
- 9. Schmitt FCF, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F, et al. Acute fibrinolysis shutdown occurs early in sep- tic shock and is associated with increased morbidity and mor- tality: Results of an observational pilot study. Ann Intensive Care 2019;9:19.
- 10. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res 2019;181:77–83.
- 11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical fea- tures of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
- 12. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemi- ological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507–13.
- 13. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020;92:791–6.
- 14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054–62.
- 15. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Ma- jor hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circula- tion 2007;115:2689–96.
- 16. Patel P, Sengupta N. PPIs and beyond: A framework for man- aging anticoagulation-related gastrointestinal bleeding in the era of COVID-19. Dig Dis Sci 2020;65:2181–6.
| APA | KARTAL s, kongur e, Ozdemir A, Öztürk Ç, Arslan M (2023). Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. , 40 - 45. 10.14744/hnhj.2021.60024 |
| Chicago | KARTAL seyfi,kongur esra,Ozdemir Abdullah,Öztürk Çağatay Erman,Arslan Mustafa Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. (2023): 40 - 45. 10.14744/hnhj.2021.60024 |
| MLA | KARTAL seyfi,kongur esra,Ozdemir Abdullah,Öztürk Çağatay Erman,Arslan Mustafa Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. , 2023, ss.40 - 45. 10.14744/hnhj.2021.60024 |
| AMA | KARTAL s,kongur e,Ozdemir A,Öztürk Ç,Arslan M Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. . 2023; 40 - 45. 10.14744/hnhj.2021.60024 |
| Vancouver | KARTAL s,kongur e,Ozdemir A,Öztürk Ç,Arslan M Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. . 2023; 40 - 45. 10.14744/hnhj.2021.60024 |
| IEEE | KARTAL s,kongur e,Ozdemir A,Öztürk Ç,Arslan M "Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit." , ss.40 - 45, 2023. 10.14744/hnhj.2021.60024 |
| ISNAD | KARTAL, seyfi vd. "Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit". (2023), 40-45. https://doi.org/10.14744/hnhj.2021.60024 |
| APA | KARTAL s, kongur e, Ozdemir A, Öztürk Ç, Arslan M (2023). Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. Haydarpaşa Numune Medical Journal, 63(1), 40 - 45. 10.14744/hnhj.2021.60024 |
| Chicago | KARTAL seyfi,kongur esra,Ozdemir Abdullah,Öztürk Çağatay Erman,Arslan Mustafa Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. Haydarpaşa Numune Medical Journal 63, no.1 (2023): 40 - 45. 10.14744/hnhj.2021.60024 |
| MLA | KARTAL seyfi,kongur esra,Ozdemir Abdullah,Öztürk Çağatay Erman,Arslan Mustafa Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. Haydarpaşa Numune Medical Journal, vol.63, no.1, 2023, ss.40 - 45. 10.14744/hnhj.2021.60024 |
| AMA | KARTAL s,kongur e,Ozdemir A,Öztürk Ç,Arslan M Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. Haydarpaşa Numune Medical Journal. 2023; 63(1): 40 - 45. 10.14744/hnhj.2021.60024 |
| Vancouver | KARTAL s,kongur e,Ozdemir A,Öztürk Ç,Arslan M Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. Haydarpaşa Numune Medical Journal. 2023; 63(1): 40 - 45. 10.14744/hnhj.2021.60024 |
| IEEE | KARTAL s,kongur e,Ozdemir A,Öztürk Ç,Arslan M "Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit." Haydarpaşa Numune Medical Journal, 63, ss.40 - 45, 2023. 10.14744/hnhj.2021.60024 |
| ISNAD | KARTAL, seyfi vd. "Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit". Haydarpaşa Numune Medical Journal 63/1 (2023), 40-45. https://doi.org/10.14744/hnhj.2021.60024 |
